HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s share price rose 0.3% on Wednesday . The company traded as high as $3.16 and last traded at $3.1599. Approximately 4,000 shares traded hands during mid-day trading, an increase of 366% from the average daily volume of 859 shares. The stock had previously closed at $3.15.
HLS Therapeutics Price Performance
The stock’s 50 day moving average price is $3.27 and its two-hundred day moving average price is $3.32.
About HLS Therapeutics
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
Recommended Stories
- Five stocks we like better than HLS Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-inc-logo-1200x675.png){kind=logo}
